Colchicine in Periprocedural Myocardial Infarction: the Role of Alpha Defensin
1 other identifier
interventional
180
1 country
1
Brief Summary
The aim of this research is to study the effect of a loading dose of colchicine on the occurrence of periprocedural myocardial infarction (PPMI) in elective percutaneous coronary intervention.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Nov 2018
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2018
CompletedFirst Submitted
Initial submission to the registry
November 7, 2018
CompletedFirst Posted
Study publicly available on registry
November 8, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2020
CompletedNovember 8, 2018
November 1, 2018
1.7 years
November 7, 2018
November 7, 2018
Conditions
Outcome Measures
Primary Outcomes (1)
Occurrence of PPMI post elective PCI
Occurrence of PPMI post elective PCI and its relation to defensin levels
24 hours post PCI
Secondary Outcomes (2)
Traditional inflammatory markers
24 hours post PCI
Major adverse cardiovascular events
30 days
Study Arms (3)
Control Group
ACTIVE COMPARATORStable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment
Early colchicine loading dose
ACTIVE COMPARATORStable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment plus colchicine loading dose 12-24 hours before PCI
Late colchicine loading dose
ACTIVE COMPARATORStable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment plus colchicine loading dose one hour prior to PCI
Interventions
Two milligrams of colchicine will be administrated in addition to the standard of care treatment
All medications normally given to patients prior to elective PCI
Eligibility Criteria
You may qualify if:
- Patients hospitalized with troponin negative events and scheduled for elective PCI
You may not qualify if:
- Significant renal dysfunction
- Significant liver dysfunction
- Severe left ventricular dysfunction
- Severe low weight
- Chronic colchicine treatment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hille Yaffe Medical Center
Hadera, 38100, Israel
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 7, 2018
First Posted
November 8, 2018
Study Start
November 1, 2018
Primary Completion
July 1, 2020
Study Completion
July 1, 2020
Last Updated
November 8, 2018
Record last verified: 2018-11
Data Sharing
- IPD Sharing
- Will not share